
Money for AI-powered drug discovery
Antiverse Ltd has reported the discovery of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both of which are...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

5 Alarm Bio Ltd raises £500K in seed round
Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, as well as other angel investors participated in Five Alarm Bio’s (FAB) seed round with...

Abionyx Pharma announces success in fighting sepsis-triggered AKI
After AM-Pharma’s human recombinant alkaline phosphatase, ilofotase alfa, missed the endpoint of improving overall survival in patients with...

Upping sustainability in pharma packaging
From glass vials, over cardboard applications, and biodegradable containers, at the PHARMAPACK Europe 2023 taking place on February 1st and 2nd in...

HOOKIPA bags US$10m cancer milestone
The Vienna-based arenavirus specialist got the non-dilutive milestone payment for advancing its drug programme HB-700, a novel arenaviral...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...